novo nordisk is cutting prices on its popular glp-1 drugs. WEIGHT-LOSS DRUG THE DECLINE! This downward trend isn’t limited to a single medication. As competition increases and more treatment options enter the market, the overall cost of medically Novo Nordisk rolls out lower
Description
10.1186/s12933-019-0857-6 9 BojerA

How this renal protection occurs is still unknown

HFpEF is especially associated with age as well as female sex and conditions such as diabetes, obesity, hypertension, coronary heart disease and CKD
In addition to providing long-term weight loss and possibly remission of T2DM, bariatric surgery is not feasible for large populations, has specific indications, and may result in surgical complications as well as other issues like malabsorption and micronutrient deficiencies
However, the functional effects of GLP-1 hormone on healthy and obese subjects in blood glucose control make T2DM a suitable target for treatment

GLP-1RAs, such as semaglutide and liraglutide, are synthetic analogs resistant to enzymatic degradation, providing prolonged, direct receptor activation
